Biologics Market Global Overview 2017 Including: Biologics, Therapeutic Proteins, Biological Drugs, Monoclonal Antibodies (MAbS), Vaccines.Covering: Amgen, AbbVie, Johnson & Johnson, Bristol-Myers Squibb Company, Pfizer, Eli Lilly, F. Hoffmann-La Roche Ltd, Merck & Co., GlaxosmithKline, Novo Nordisk
The global biologics market is expected to reach around $291 billion in 2020. This can be attributed to the increasing evidence of positive responses to treatment with biologics, availability of advanced diagnostics increasing the treatment population, and rising government initiatives for the research and development of biologics globally thereby increasing the acceptance of the products in the market and increasing amount of patient population using the biologics.
Biologics Market Global Briefing provides strategists, marketers and senior management with the critical information they need to assess the global biologics sector.
Reasons to Purchase
Get up to date information available on the biologics market globally.
Identify growth segments and opportunities.
Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
Develop strategies based on likely future developments.
Gain a global perspective on the development of the market.
Biologics Market Global Briefing from the Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.
The market characteristics section of the report defines and explains the market.
The market size section gives the biologics market revenues, covering both the historic growth of the market and forecasting the future.
Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.
The trends and strategies section highlights the likely future developments in the biologics market and suggests approaches.